[1]熊星?王志梅 张宁 温霞.甘油三酯葡萄糖指数和血小板与淋巴细胞比值在心血管疾病中的研究进展[J].心血管病学进展,2024,(11):1021.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.014]
　XIONG Xing,WANG Zhimei,ZHANG Ning,et al.Triglyceride-Glucose Index and Platelet-to-Lymphocyte Ratio?n Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2024,(11):1021.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.014]
点击复制

甘油三酯葡萄糖指数和血小板与淋巴细胞比值在心血管疾病中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年11期
页码:
1021
栏目:
综述
出版日期:
2024-11-25

文章信息/Info

Title:
Triglyceride-Glucose Index and Platelet-to-Lymphocyte Ratio?n Cardiovascular Diseases
作者:
熊星1?王志梅1 张宁1 温霞2
(1.内蒙古医科大学内蒙古临床医学院,内蒙古 呼和浩特 010020;2内蒙古自治区人民医院急诊科,内蒙古 呼和浩特 010020)
Author(s):
XIONG Xing1;  WANG Zhimei1;  ZHANG Ning1;  WEN Xia2?/html>
?1. Inner Mongolia Clinical Medical College,Inner Mongolia Medical University,Hohhot 010020,Inner Mongolia,China; 2.Department of Emergency,Inner Mongolia Autonomous Region People’s Hospital,Hohhot 010020,Inner Mongolia,China)
关键词:
血管疾病; 临床指标; 甘油三酯葡萄糖指数血小板与淋巴细胞比值
Keywords:
Cardiovascular disease;  Clinical indicators;  Triglyceride-glucose index;  Platelet-to-lymphocyte ratio
DOI:
10.16806/j.cnki.issn.1004-3934.2024.11.014
摘要:
心血管疾病（CVD）是引起全球发病率和死亡率持续升高的慢性非传染性疾病，吸烟、肥胖和血脂异常等多因素共同参与其发病过程，对公共卫生构成了严重的威胁和挑战。因此，亟需探索新的有效风险预测因子及干预措施，准确识别高危患者，“前移”预防窗口，控制致病危险因素、延缓病程进展己成为防治CVD的根本。甘油三酯葡萄糖指数通过代谢及炎症反应等途径驱动动脉粥样硬化的形成，从而加剧向冠心病的演变过程；在血管内皮功能、血管紧张素原的异位合成、肾素-血管紧张素-醛固酮系统、交感神经系统及盐吸收中发挥作用，从而影响血压的变化；此外，随着胰岛素抵抗程度的增加，心脏脂肪酸利用率下降、AMPK/PGC-1信号转导通路损害及活性氧水平增加，从而导致心力衰竭的发生。血小板与淋巴细胞比值是一种炎症标志物，通过血小板和淋巴细胞的变化在CVD中发挥作用。结合最新研究对以上两个指标预测CVD的潜在价值进行综述
Abstract:
Cardiovascular disease (CVD) is a chronic non-infectious disease that causes the global incidence rate and mortality to continue to rise. Smoking,obesity,dyslipidemia and other factors participate in its pathogenesis,posing a serious threat and challenge to public health. Therefore,it is urgent to explore new effective risk prediction factors and intervention measures,accurately identify high-risk patients,move forward the prevention window,control pathogenic risk factors and delay disease progression,which have become the fundamental measures for preventing and treating CVD. Triglyceride-glucose index drives the formtion of atherosclerosis through metabolic and inflammatory pathways,thus exacerbating the evolution to coronary heart disease. It also plays a role in vascular endothelial function,ectopic synthesis of angiotensinogen,renin-angiotensin-aldosterone system,sympathetic nervous system and salt absorption,thus affecting blood pressure changes. In addition,with the increase of insulin resistance,the utilization of cardiac fatty acids decreased,AMPK/PGC-1 signal transduction pathway impaired,and reactive oxygen species levels increased,leading to the occurrence of heart failure. The platelet-to-lymphocyte ratio is an inflammatory marker that plays a role in CVD through changes in platelets and lymphocytes.Based on the latest research，this article reviews the potential value of the above two indicators in predicting CVD

参考文献/References:

[1] Gan T,Hu J,Liu W,et al. Causal association between anemia and cardiovascular disease:a 2‐sample bidirectional mendelian randomization study[J]. J Am Heart Assoc,2023,12(12):e029689.
[2] Tsao CW,Aday AW,Almarzooq ZI,et al. Heart disease and stroke statistics—2022 update:a report from the American Heart Association[J]. Circulation,2022,145(8):e153-e639.
[3] Ma X,Dong L,Shao Q,et al. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome[J]. Cardiovasc Diabetol,2020,19(1):31.
[4] Chen T,Yang M. Platelet-to-lymphocyte ratio is associated with cardiovascular disease in continuous ambulatory peritoneal dialysis patients[J]. Int Immunopharmacol,2020,78:106063.
[5] Takeuchi T,Kubota T,Nakanishi Y,et al. Gut microbial carbohydrate metabolism contributes to insulin resistance[J]. Nature,2023,621(7978):389-395.
[6] Guo X,Shen R,Yan S,et al. Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention[J]. Cardiovasc Diabetol,2023,22(1):43.
[7] Hill MA,Yang Y,Zhang L,et al. Insulin resistance,cardiovascular stiffening and cardiovascular disease[J]. Metabolism,2021,119:154766.
[8] Tao LC,Xu JN,Wang TT,et al. Triglyceride-glucose index as a marker in cardiovascular diseases:landscape and limitations[J]. Cardiovasc Diabetol,2022,21(1):68.
[9] Sanchez-Garcia A,Rodriguez-Gutierrez R,Mancillas-Adame L,et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance:a systematic review[J]. Int J Endocrinol,2020,2020:4678526.
[10] Xu X,Huang R,Lin Y,et al. High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life:insight from the CARDIA study[J]. Cardiovasc Diabetol,2022,21(1):155.
[11] Mahdavi-Roshan M,Salari A,Vakilpour A,et al. Rice bran oil could favorably ameliorate atherogenicity and insulin resistance indices among men with coronary artery disease:post hoc analysis of a randomized controlled trial[J]. Lipids Health Dis,2021,20(1):153.
[12] di Pino A,DeFronzo RA. Insulin resistance and atherosclerosis:implications for insulin-sensitizing agents[J]. Endocr Rev,2019,40(6):1447-1467.
[13] Hong S,Han K,Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease:a population-based study[J]. BMC Med,2020,18(1):361.
[14] Kim S,Lee JW,Lee Y,et al. Association between triglyceride-glucose index and low-density lipoprotein particle size in korean obese adults[J]. Lipids Health Dis,2023,22(1):94.
[15] Song S,Choi SY,Park HE,et al. Incremental prognostic value of triglyceride glucose index additional to coronary artery calcium score in asymptomatic low-risk population[J]. Cardiovasc Diabetol,2022,21(1):193.
[16] Li J,Dong Z,Wu H,et al. The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease,regardless of diabetes mellitus and hyperlipidaemia[J]. Cardiovasc Diabetol,2023,22(1):224.
[17] Bax JJ,Achenbach S,Valgimigli M,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.
[18] Love KM,Liu Z. DPP4 activity,hyperinsulinemia,and atherosclerosis[J]. J Clin Endocrinol,2021,106(6):1553-1565.
[19] Ma Y,Zhen Y,Wang M,et al. Associations between the serum triglyceride-glucose index and pericoronary adipose tissue attenuation and plaque features using dual-layer spectral detector computed tomography:a cross-sectional study[J]. Front Endocrinol (Lausanne),2023,14:1166117.
[20] Alizargar J,Bai CH,Hsieh NC,et al. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients[J]. Cardiovasc Diabetol,2020,19(1):8.
[21] Thai PV,Tien HA,van Minh H,et al. Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes[J]. Cardiovasc Diabetol,2020,19(1):137.
[22] Park GM,Cho YR,Won KB,et al. Triglyceride glucose index is a useful marker for predicting subclinical coronary artery disease in the absence of traditional risk factors[J]. Lipids Health Dis,2020,19(1):7.
[23] Mahdavi-Roshan M,Mozafarihashjin M,Shoaibinobarian N,et al. Evaluating the use of novel atherogenicity indices and insulin resistance surrogate markers in predicting the risk of coronary artery disease:a case-control investigation with comparison to traditional biomarkers[J]. Lipids HealthDis,2022,21(1):126.
[24] Mills KT,Stefanescu A,He J. The global epidemiology of hypertension[J]. Nat Rev Nephrol,2020,16(4):223-237.
[25] Li Y,Choi JW,Park JS,et al. Interactive effect of high sodium intake with increased serum triglycerides on hypertension[J]. Plos One,2020,15(4):e0231707.
[26] Gao Q,Lin Y,Xu R,et al. Positive association of triglyceride-glucose index with new-onset hypertension among adults:a national cohort study in China[J]. Cardiovasc Diabetol,2023,22(1):58.
[27] Tanaka M. Improving obesity and blood pressure[J]. Hypertens Res,2019,43(2):79-89.
[28] Wang K,He G,Zhang Y,et al. Association of triglyceride-glucose index and its interaction with obesity on hypertension risk in Chinese:a population-based study[J]. J Hum Hypertens,2021,35(3):232-239.
[29] Lee DH,Park JE,Kim SY,et al. Association between the triglyceride-glucose (TyG) index and increased blood pressure in normotensive subjects:a population-based study[J]. Diabetol Metab Syndr,2022,14(1):161.
[30] Du T,Yuan G,Zhang M,et al. Clinical usefulness of lipid ratios,visceral adiposity indicators,and the triglycerides and glucose index as risk markers of insulin resistance[J]. Cardiovasc Diabetol,2014,13(1):146.
[31] Zhang F,Hou X. Association between the triglyceride glucose index and heart failure:NHANES 2007-2018[J]. Front Endocrinol,2024,14:1322445.
[32] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[33] Lopaschuk GD,Karwi QG,Tian R,et al. Cardiac energy metabolism in heart failure[J]. Circ Res,2021,128(10):1487-1513.
[34] Jia G,Whaley-Connell A,Sowers JR. Diabetic cardiomyopathy:a hyperglycaemia- and insulin-resistance-induced heart disease[J]. Diabetologia,2017,61(1):21-28.
[35] Henstridge DC,Whitham M,Febbraio MA. Chaperoning to the metabolic party:The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes[J]. Mol Metab,2014,3(8):781-793.
[36] Guo W,Zhao L,Mo F,et al. The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes:A retrospective cohort study[J]. Diabetes Res Clin Pract,2021,177:108786.
[37] Yang S,Du Y,Liu Z,et al. Triglyceride-glucose index and extracellular volume fraction in patients with heart failure[J]. Front Cardiovasc Med,2021,8:704462.
[38] Zhou Q,Yang J,Tang H,et al. High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol,2023,22(1):263.
[39] Xie H,Song J,Sun L,et al. Independent and combined effects of triglyceride-glucose index on prehypertension risk:a cross-sectional survey in China[J]. J Hum Hypertens,2021,35(3):207-214.
[40] Ye GL,Chen Q,Chen X,et al. The prognostic role of platelet-to-lymphocyte ratio in patients with acute heart failure:a cohort study[J]. Sci Rep,2019,9(1):10639.
[41] Panni RZ,Lopez-Aguiar AG,Liu J,et al. Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG)[J]. J Surg Oncol,2019,120(4):632-638.
[42] Dong G,Huang A,Liu L. Platelet‐to‐lymphocyte ratio and prognosis in STEMI:a meta‐analysis[J]. Eur J Clin Invest,2020,51(3):e13386.
[43] Kurtul A,Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases:a systematic review[J]. Angiology,2019,70(9):802-818.
[44] Massiot N,Lareyre F,Voury-Pons A,et al. High neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with symptomatic internal carotid artery stenosis[J]. J Stroke Cerebrovasc Dis,2019,28(1):76-83.
[45] Zhou D,Wang G,Fan Y,et al. Platelet to lymphocyte ratio is associated with the severity of coronary artery disease and clinical outcomes of percutaneous coronary intervention in the Chinese Han population[J]. Exp Ther Med,2017,13(2):731-738.
[46] Qiu Z,Jiang Y,Jiang X,et al. Relationship between platelet to lymphocyte ratio and stable coronary artery disease:meta-analysis of observational studies[J]. Angiology,2020,71(10):909-915.
[47] Li L,Ma Y,Geng Xb,et al. Platelet-to-lymphocyte ratio relates to poor prognosis in elderly patients with acute myocardial infarction[J]. Aging Clin Exp Res,2021,33(3):619-624.
[48] Wang J,Kang Z,Liu Y,et al. Identification of immune cell infiltration and diagnostic biomarkers in unstable atherosclerotic plaques by integrated bioinformatics analysis and machine learning[J]. Front Immunol,2022,13:956078.
[49] Paolisso P,Foà A,Bergamaschi L,et al. Hyperglycemia,inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA[J]. Cardiovasc Diabetol,2021,20(1):33.
[50] Wang X,Xie Z,Liu X,et al. Association of Platelet to lymphocyte ratio with non-culprit atherosclerotic plaque vulnerability in patients with acute coronary syndrome:an optical coherence tomography study[J]. BMC Cardiovasc Disord,2017,17(1):175.
[51] Larmann J,Handke J,Scholz AS,et al. Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery[J]. BMC Cardiovasc Disord,2020,20(1):230.
[52] Azab B,Shah N,Akerman M,et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction[J]. J Thromb Thrombolysis,2012,34(3):326-334.
[53] Litwin M,Feber J,Niemirska A,et al. Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities[J]. Pediatr Nephrol,2016,31(2):185-194.
[54] Skrzypczyk P,Bujanowicz A,Ofiara A,et al. 24-hour central blood pressure and immune system activation in adolescents with primary hypertension—A preliminary study[J]. Cent Eur J Immunol,2022,47(2):160-167.
[55] Seo IH,Lee YJ. Usefulness of complete blood count (CBC) to assess cardiovascular and metabolic diseases in clinical settings:a comprehensive literature review[J]. Biomedicines,2022,10(11):2697.
[56] Barhoumi T,Kasal DA,Li MW,et al. T regulatory lymphocytes prevent angiotensin Ⅱ-induced hypertension and vascular injury[J]. Hypertension,2011,57(3):469-476.
[57] Pinho R,Ribeiro R,Ferr?o D,et al. The platelet-to-lymphocyte ratio as an indirect outcome predictor in primary hypertension:a retrospective study[J]. Porto Biomed J,2023,8(4):e220.
[58] Drugescu A,Roca M,Zota IM,et al. Relationships between easily available biomarkers and non-dipper blood pressure pattern in patients with stable coronary artery disease[J]. Life (Basel),2023,13(3):640.
[59] Heidarpour M,Bashiri S,Vakhshoori M,et al. The association between platelet-to-lymphocyte ratio with mortality among patients suffering from acute decompensated heart failure[J]. BMC Cardiovasc Disord,2021,21(1):454.
[60] ?ak?r MO. The prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for long-term survival in patients with severe left ventricular dysfunction and implantable cardioverter defibrillator[J]. Cureus,2023, 15(10):e47441.
[61] Delcea C,Buzea CA,V?jan AE,et al. The platelet to lymphocyte ratio in heart failure:a comprehensive review[J]. Rom J Intern Med,2023,61(2):84-97.
[62] Delcea C,Buzea CA,Vijan A,et al. Comparative role of hematological indices for the assessment of in-hospital outcome of heart failure patients[J]. Scand Cardiovasc J,2021,55(4):227-236.
[63] Dahlen B,Schulz A,G?bel S,et al. The impact of platelet indices on clinical outcome in heart failure:results from the MyoVasc study[J]. ESC Heart Fail,2021,8(4):2991-3001.

更新日期/Last Update: 2024-12-02